First Trust Advisors LP Takes $735,000 Position in AMAG Pharmaceuticals, Inc. (AMAG)

First Trust Advisors LP purchased a new stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 39,843 shares of the specialty pharmaceutical company’s stock, valued at approximately $735,000. First Trust Advisors LP owned approximately 0.11% of AMAG Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. State Street Corp increased its stake in shares of AMAG Pharmaceuticals by 10.6% in the 2nd quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock valued at $51,336,000 after purchasing an additional 267,873 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of AMAG Pharmaceuticals by 18.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock valued at $22,361,000 after purchasing an additional 189,576 shares in the last quarter. Gotham Asset Management LLC increased its stake in shares of AMAG Pharmaceuticals by 17.8% in the 2nd quarter. Gotham Asset Management LLC now owns 800,055 shares of the specialty pharmaceutical company’s stock valued at $14,721,000 after purchasing an additional 121,137 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of AMAG Pharmaceuticals by 1.7% in the 2nd quarter. Renaissance Technologies LLC now owns 778,800 shares of the specialty pharmaceutical company’s stock valued at $14,330,000 after purchasing an additional 12,800 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of AMAG Pharmaceuticals by 23.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 651,708 shares of the specialty pharmaceutical company’s stock valued at $12,025,000 after purchasing an additional 125,719 shares in the last quarter.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at $13.95 on Thursday. AMAG Pharmaceuticals, Inc. has a 52 week low of $11.93 and a 52 week high of $36.83. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.

Several equities analysts recently weighed in on AMAG shares. Jefferies Group restated a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Wednesday, October 4th. Deutsche Bank restated a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, Cowen restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $24.00.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/07/first-trust-advisors-lp-takes-735000-position-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit